Medpace Holdings, Inc. $MEDP Shares Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 92.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 347,049 shares of the company’s stock after buying an additional 166,654 shares during the period. Goldman Sachs Group Inc.’s holdings in Medpace were worth $194,920,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Westpac Banking Corp acquired a new stake in shares of Medpace during the fourth quarter worth $260,000. Natixis Advisors LLC lifted its stake in shares of Medpace by 8.9% during the fourth quarter. Natixis Advisors LLC now owns 163,360 shares of the company’s stock worth $91,751,000 after buying an additional 13,412 shares during the period. Fielder Capital Group LLC lifted its stake in shares of Medpace by 11.9% during the fourth quarter. Fielder Capital Group LLC now owns 818 shares of the company’s stock worth $459,000 after buying an additional 87 shares during the period. Florida Financial Advisors LLC acquired a new stake in shares of Medpace during the fourth quarter worth $260,000. Finally, Rothschild Wealth LLC acquired a new stake in shares of Medpace during the fourth quarter worth $568,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday, February 11th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Leerink Partners decreased their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Royal Bank Of Canada decreased their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $467.08.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Medpace Price Performance

MEDP opened at $454.25 on Friday. The firm has a fifty day moving average price of $456.73 and a 200 day moving average price of $508.93. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92. The stock has a market cap of $12.97 billion, a P/E ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the previous year, the company earned $3.67 earnings per share. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.